Endra Life Sciences Inc. · NASDAQ:NDRA
Endra Life Sciences — Investor Presentation (March 2021)
19 slides from Endra Life Sciences's investor presentation, Mar 5, 2021
Slide 1: Practical Assessment of Hepatic Steatosis for NAFLD-NASH
Practical Assessment of Hepatic Steatosis for NAFLD - NASH INVESTOR PRESENTATION MARCH 2021 ENDRA LIFE SCIENCES ‘See more, Do mor. Live beter: ® NASDAQ: NORA
Slide 2: Forward-Looking Statements
Forward-Looking Statements Cerein statements made inthis presentation are forwardiakng statements Al statements ater than statements of hstoncal facts cortined inthis resertavon cluding statements regarding the ting of our cca ala, our strategy, Mure operatons. ture fal postin. itr’ revene. projecte
Slide 3: ENDRA Life Sciences' Goal
ENDRA Life Sciences’ Goal SEE MORE. DO MORE. LIVE BETTER. ® Commercialize Thermo Acoustic Enhanced UltraSound (TAEUS®), a technology that enhances existing ultrasound systems to visualize tissue similar to an MRI, but at SOX" lower cost and at the point of patient care. DeNoRA nasoaa none 3)
Slide 4: ENDRA Life Sciences
ENDRA Life Sciences PLATFORM TECHNOLOGY 4 APPLICATION: LIVER DISEASE OPERATIONS & PARTNERS Opportunities in a variety of 1.4B people? affected by excess Lean operations: “20 employees, clinical applications liver fat: and inflammation ‘Ann Arbor, Michigan ‘Multiple potential revenue ~50 pharma thera
Slide 5: TAEUS Platform Evolution
TAEUS® Platform Evolution: MULTIPLE POTENTIAL CLINICAL APPLICATIONS & REVENUE STREAMS TO SCALE BUSINESS HARDWARE ‘SOFTWARE SERVICES DISPOSABLES LICENSING Accessorytoincrease — SWappsaddedt Eg. Maintenance Eg. Applicator pods uid TAEUS into new OEM Ulity of existing TAEUS accessoryor contracts —«‘wen
Slide 6: Large Unmet Clinical Need: NAFLD-NASH Diagnostics
Large Unmet Clinical Need: NAFLD-NASH Diagnostics RAMPANT DISEASE, APPROACHING THERAPIES ... BUT NO PRACTICAL DIAGNOSTIC TOOLS Diagnostic Gap 1® Therapies Near 1.4 billion people affected.’ Linked to obesity, diabetes, genetics Can progress to fibrosis, cirrhosis cancer and cardiovascular disease” A
Slide 7: Assessing & Monitoring Liver Fat of Billion NAFLD-NASH Patients
Assessing & Monitoring Liver Fat of 1 Billion* NAFLD-NASH Patients NO TOOL HAS BALANCED DIAGNOSTIC VALUE + ACCESSIBILITY HIGH i i OPTIMAL BALANCE 6 | _DIAGNOSTIC VALUE + ACCESSIBILITY y DIAGNOSTIC VALUE Low ACCESSIBILITY HIGH (AFFORDABILITY, SAFETY, EASE OF USE) NASDAG: NORA 7
Slide 8: ENDRA's TAEUS: Enhancing Traditional Ultrasound
ENDRA’s TAEUS®: Enhancing Traditional Ultrasound RADIO FREQUENCY PULSES CREATE SONIC WAVES THAT QUANTITATE LIVER FAT FRACTION pS ¥ TAEUS directly measures a material property of liver tissue that is only affected by the amount of fat (triglyceride}, and has not been found to be confounded by fibrosi
Slide 9: TAEUS Liver: Targeting High-Value Segments
TAEUS® Liver: Targeting High-Value Segments CLINICIANS & DRUG DEVELOPERS STRUGGLE WITH MRI-BIOPSY LIMITATIONS IMAGING EXPERTS LIVER EXPERTS: METABOLISM & DRUG DEVELOPERS Radiology Gastro-Hepatology LIFESTYLE EXPERTS Pharma & CRO’s -100,000 - 45,000 -300,000 “50 therapies in practitioners? practition
Slide 10: TAEUS Liver Commercialization: Core Strategies
TAEUS Liver Commercialization: 3 Core Strategies ENDRA LIFE SCIENCES. Lan onesnons reer G0u22 @enoea NASDAG:NORA 4g
Slide 11: Global Environment
Global Environment DESPITE 2020 HEADWINDS... ENDRA IS POSITIONED FOR SUCCESS IN 2021 Encouraging signs of progress at healthcare provider level Global MRI imaging (used for comparison in ENDRA\s clinical studies) has been experiencing 3 to 8 week backlogs, driven by: + Reduced hospital staff availab
Slide 12: Anticipated Milestones: ENDRA Liver Application
Anticipated Milestones: ENDRA Liver Application BUILD CLINICAL EVIDENCE, SECURE US REGULATORY APPROVAL, RAMP COMMERCIALIZATION 2021 + Receive FDA 510{k) clearance + Ramp commercialization in EU & US; first revenue from sale of TAEUS + Collect & publish TAEUS clinical evidence from global reference p
Slide 13: Financial Information
Financial Information enone KEY STATISTICS Cash Balance? Common Shares Outstanding Fully Diluted Shares Outstanding Market Capitalization? Management / Director Ownership? Feb 28, 2021 ProForma’ $9.5M 38.5M 446M $96.3M 10.9% ‘broom Ftran 28, 202 have tte it ond oe ne tress on camera wean se saree TM
Slide 14: Appendix
APPENDIX QENDRA
Slide 15: Leadership & Advisors
Leadership & Advisors ‘g $ % &% Francois Michelon Michael Thornton Renaud Maloberti Ghairman & CEO cro coo 20° yearsinmedtech 18 yearsmedtech 20" yearsin medtech 12 GEHoathcare. Smith S Founder Enhanced soe seein Nephew. Biomet Vion Sytem (eoldto GE) Fuji, BK Medical, CE Heakncare INDEPENDENT DIRECT
Slide 16: Future TAEUS Application: Guidance of Energy-Based Surgery
Future TAEUS Application: Guidance of Energy-Based Surgery SHOW HEAT OR COLD SIGNATURE OF THERMO-ABLATIVE PROCEDURES FOR CANCER, CARDIOLOGY, PAIN ‘THERMO-ABLATIVE PROCEDURES: * 5¢ million procedures annually growing at 15%" CAGR, driven by agingrelated diseases: cancer, pain, cardiology ), * Current
Slide 17: Expected TAEUS Economic & Clinical Value To Stakeholders
Expected TAEUS Economic & Clinical Value To Stakeholders PATIENTS HEALTHCARE PROVIDERS ‘PAYERS: Ultrasound Procedure TAEUS Procedure Education & Reimbursement ae ct ac ectrremtenanmmermes | | cacansnmnatarsahticn | | PaTanaiersentto st | | 5 cncinnarasn Tut jertieay pete eas pete eaoatertontntios |
Slide 18: Liver Fat Measurement Tool: Relative Performance & Accessibility
Liver Fat Measurement Tool: Relative Performance & Accessibility Mognetic Resonance moped MA oon ga. ns ae = Mase ty rca rc OM SOM ost.o9 070 - fave Nearecoronae rs ets ira LSE) asia apie rng Vr rma oer prt Aamir Bosogrooy = Seenevetetersecereerv ein, nioeracsmnemcnnstinmnyts 070-085 O78:087 070.001
Slide 19: Sources & Assumptions
Sources & Assumptions 1 fae ti iets fates nd en tert pte 2 tangy Te corer wd ie ety rnin he ed Sinn ee Yon Ese ry Spr Rtn ha ran 2018 2 Gun fees 2080 (a Die ares Mri Exit § De kas Eeamveaee PAGE 6 1) Me ANC ore Waa an Nate 204 2 Grams Nett an an att ec Se Ry ne 2 Hla Te coer rd rc rf ot ay em nee ‘S
ENDRA Life Sciences — Investor Presentation (March 2021) on 6ix